RAPT: RAPT Therapeutics Price to Sales
The valuation of RAPT Therapeutics, Inc. (RAPT) is based on future patent protection for immune therapies, which allows the company to exercise pricing power. The price-to-sales ratio illustrates valuation deviations from the norm, where the value of 810.70 expresses the metric level. The current balance sheet is supported by prudent funding of clinical trials, while R&D development in oncology and inflammation provides growth potential.
RAPT Therapeutics, Inc. (RAPT) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity RAPT Therapeutics, Inc.|RAPT - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio rapt.com|RAPT - Company Total Debt|Debt to Net Assets Ratio RAPT|RAPT - Company Long-Term Liabilities|Amount of Current Liabilities RAPT Therapeutics|Intermediate Coverage Ratio rapt.com
- earnings and valuation multiples information:
RAPT - Net Profit|Expected Net Profit RAPT Therapeutics, Inc.|RAPT - Price to Earnings Ratio|Future Price to Earnings Multiple RAPT Therapeutics Inc.|RAPT - PEG Multiple|EV/EBITDA Multiple RAPT|RAPT - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months RAPT Therapeutics|RAPT - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months rapt.com|RAPT - Net earnings per share growth this year|Earnings growth forecast for next year RAPT Therapeutics, Inc.
- issuer revenue and sales details:
Summary company analytics:RAPT Therapeutics Inc., RAPT
For RAPT Therapeutics, Inc. (RAPT), which operates in the high-risk immunological development segment, the company's P/S ratio serves as an indicator of market expectations regarding the commercialization of its patented molecules. This ratio is calculated as the relationship between market capitalization and annual revenue, allowing investors to determine the extent of the premium paid for current sales and assess the asset's stability compared to its historical values.
Who RAPT Therapeutics, Inc. competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PTGX (Protagonist Corp)|IMVT: P/S Multiple|kiniksa.com (KNSA) - P/S Multiple|Price-to-Revenue Ratio Grifols|Adaptive Biotech - Price-to-Sales Ratio|Market Cap to Revenue CLDX (Celldex)|Market Cap to Sales Volume AUPH|BioCryst - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VERA|DNTH: Market Cap to Revenue|Pharvaris NV - Market Cap to Sales Volume|ABCL: P/S Multiple|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|Price to Sales pharming.com PHAR|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|P/S Multiple Immunome Bio IMNM|GOSS - Price-to-Revenue Ratio|Price-to-Sales Ratio KALV|SEPN: P/S Multiple|Price to Sales Pieris Pharma (PVLA)|Market Cap to Revenue SVRA|P/S Multiple Rigel Corp|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|Market Cap to Sales Volume ATXS|P/S Multiple ENGN (enGene)|Price-to-Revenue Coefficient Aerovate Therapeutics, Inc. (JBIO)|Aclaris - P/S Multiple|Kyverna Therapeutics, Inc (KYTX) - Market Cap to Revenue|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|CABA - Price-to-Revenue Coefficient|Market Cap to Revenue VTYX|THTX: Market Capitalization-to-Revenue Ratio|P/S Multiple AVTX|Price-to-Revenue Coefficient Eledon Pharmaceuticals, Inc|Price-to-Revenue Ratio Agenus AGEN|CLYM: Market Cap to Revenue Ratio|Zura Bio - P/S Multiple|aTyr Pharma Inc (ATYR) - Market Cap to Revenue|ADAG (adagene.com) - Market Cap to Revenue|IMA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Shattuck Labs Inc|EQ: Market Capitalization-to-Revenue Ratio|P/S Multiple CNTB|P/S Multiple immunic-therapeutics.com (IMUX)|Price-to-Revenue Ratio Atara Bio ATRA|IFRX (InflaRx NV) - Price-to-Sales Ratio|XFOR: Market Cap to Revenue|Adicet Bio - Market Cap to Sales Volume|celularity.com (CELU) - Price-to-Revenue Ratio|Price-to-Sales Ratio INMB (INmune Bio Inc)|BRNS (Barinthus Bio) - P/S Multiple|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|P/S Multiple akaritx.com (AKTX)|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|Market Capitalization-to-Revenue Ratio QTTB|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|Carisma Therapeutics Inc. (CARM) - P/S Multiple|Market Cap to Revenue XTLB|BOLT: Market Capitalization-to-Revenue Ratio|P/S Multiple HCWB|Price-to-Revenue Coefficient aptevotherapeutics.com|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI - Price-to-Revenue Ratio|XORTX Therapeutics Inc (XRTX) - Market Cap to Revenue|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|P/S Multiple CALI|AFMD - Price to Sales|Price-to-Revenue Ratio Allakos ALLK|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|ITOS - P/S Multiple|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Price-to-Sales Ratio TCBP (TC BioPharm (Holdings) Plc)|Market Cap to Revenue THRD
